These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 24518375)

  • 1. New drugs for gastrointestinal stromal tumors.
    Garrett C
    Clin Adv Hematol Oncol; 2013 Oct; 11(10):656-8. PubMed ID: 24518375
    [No Abstract]   [Full Text] [Related]  

  • 2. Current directions in systemic therapy for gastrointestinal stromal tumors.
    Chugh R
    Curr Probl Cancer; 2011; 35(5):255-70. PubMed ID: 22118565
    [No Abstract]   [Full Text] [Related]  

  • 3. [Novel molecular-targeted agents for GIST(Regorafenib etc.)].
    Naito Y; Doi T
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):15-8. PubMed ID: 23306914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
    Pisters PW; Colombo C
    J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing identifies therapeutic agents for gastrointestinal stromal tumors.
    Thorne J
    Future Med Chem; 2014 Apr; 6(6):602. PubMed ID: 25028758
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    DeMatteo RP
    Ann Surg Oncol; 2007 Jan; 14(1):1-2. PubMed ID: 16957967
    [No Abstract]   [Full Text] [Related]  

  • 7. Surgical options for advanced/metastatic gastrointestinal stromal tumors.
    Meza JM; Wong SL
    Curr Probl Cancer; 2011; 35(5):283-93. PubMed ID: 22118567
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical analysis of 79 gastrointestinal tract stromal tumor cases].
    Liu ZM; Liang J; Yu Z
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):552-3. PubMed ID: 22093639
    [No Abstract]   [Full Text] [Related]  

  • 9. [Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].
    Sato A; Hamada K; Imataka H
    Gan To Kagaku Ryoho; 2012 May; 39(5):708-12. PubMed ID: 22584320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib].
    Nishimura T; Sakata K; Maeda Y; Nagashima Y; Okada T; Nakamura M; Setoguchi M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2202-4. PubMed ID: 22202330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
    Parikh PM; Gupta S
    Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
    Quintero CB; Cubedo R
    Anticancer Drugs; 2012 Jun; 23 Suppl():S1-2. PubMed ID: 22739664
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
    Rediti M; Pellegrini E; Molinara E; Cerullo C; Fonte C; Lunghi A; Iori A; Neri B
    Anticancer Res; 2014 Feb; 34(2):905-7. PubMed ID: 24511030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
    Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
    Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
    Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foreword. Gastrointestinal stromal tumors.
    Delman KA
    Curr Probl Cancer; 2011; 35(5):232. PubMed ID: 22118562
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors].
    Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):801-806. PubMed ID: 31550816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ
    Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor.
    Gerin F; Baloglu O; Morgan JA; Kesari S
    J Neurooncol; 2007 Apr; 82(2):227-8. PubMed ID: 17106648
    [No Abstract]   [Full Text] [Related]  

  • 20. Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.
    Schiavon G; Eechoute K; Mathijssen RH; de Bruijn P; van der Bol JM; Verweij J; Sleijfer S; Loos WJ
    J Clin Pharmacol; 2012 Jul; 52(7):1115-20. PubMed ID: 21602518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.